Considerations To Know About Sifalimumab
MI-CP151 was a section 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre review To judge multiple intravenous doses of sifalimumab, in Grownup patients with dermatomyositis or polymyositis (NCT00533091). Most important trial objectives were being to evaluate the safety and tolerability of sifalimumab in dermatomyositis o